Voices
FDA Approves Zongertinib for HER2-Mutated NSCLC – Oncology Brothers
Oncology Brothers/X

FDA Approves Zongertinib for HER2-Mutated NSCLC – Oncology Brothers

Oncology Brothers shared a post on X:

“Zongertinib now FDA Oncology (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off Beamion LUNG1 (single arm n=72)

  • ORR: 76%
  • Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
  • New SoC.”

FDA Approves Zongertinib for HER2-Mutated NSCLC - Oncology Brothers

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

FDA Approves Zongertinib for HER2-Mutated NSCLC - Oncology Brothers

cancer FDA NSCLC OncoDaily Oncology Oncology Brothers Zongertinib